Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL419451 | 0.94 | — | — | |
| SCHEMBL16660 | 0.94 | — | — | |
| Ethylene SCHEMBL7184469 | 0.89 | GRIK1 (0.39) | GRIK1GRIK2FFAR3ALDH1A1EP300 | |
| Methacrylic Acid SCHEMBL8824600 | 0.87 | GRIK1 (0.35) | GRIK1GRIK2TDP1EP300 | |
| SCHEMBL9340600 | 0.86 | GRIK1 (0.38) | GRIK1GRIK2FFAR3EP300 | |
| SCHEMBL5698422 | 0.84 | GRIK1 (0.41) | GRIK1GRIK2FFAR3EP300LMNA | |
| Succinic Acid SCHEMBL2484907 | 0.84 | LMNA (0.45) | FFAR3ALDH1A1TDP1LMNA | |
| Phosphoric Acid SCHEMBL1137771 | 0.84 | GRIK1 (0.36) | GRIK1GRIK2FFAR3TDP1EP300 | |
| Phosphoric Acid SCHEMBL1137734 | 0.84 | GRIK1 (0.36) | GRIK1GRIK2FFAR3TDP1EP300 | |
| SCHEMBL6048309 | 0.82 | GRIK1 (0.41) | GRIK1GRIK2FFAR3ALDH1A1EP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4021951-A1 | HYDROGELS AS ORAL DELIVERY DOSAGE FORMS, METHODS OF MAKING AND USING SAME | Godfrin, Paul Douglas (US) | 2022-07-06 | — | — | EP | disclosed |
| WO-2021042043-A1 | HYDROGELS AS ORAL DELIVERY DOSAGE FORMS, METHODS OF MAKING AND USING SAME | GODFRIN PAUL DOUGLAS (US) | 2021-03-04 | — | — | WO | disclosed |
| US-20210059933-A1 | HYDROGELS AS ORAL DELIVERY DOSAGE FORMS, METHODS OF MAKING AND USING SAME | VERAMORPH LLC | 2021-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210059933-A1 | HYDROGELS AS ORAL DELIVERY DOSAGE FORMS, METHODS OF MAKING AND USING SAME | HPGDS, HLCS, CD44 | GRIK1 3096/4885GRIK2 3264/4885FFAR3 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.